Peptide Research Index
⚠️ Educational only · Not medical advice · Consult a doctor · Most peptides are research-only / not FDA-approved for human use
⚠️ Educational only · Not medical advice · Consult a doctor · Most peptides are research-only / not FDA-approved for human use
Also: Nicotinamide Adenine Dinucleotide, NAD Plus, Beta-Nicotinamide Adenine Dinucleotide
LongevityLast Updated: April 1, 2026
NAD+ (also known as Nicotinamide Adenine Dinucleotide, NAD Plus, Beta-Nicotinamide Adenine Dinucleotide) is a prominently researched experimental compound classified strictly within the Longevity framework. Operating primarily through advanced pharmacological pathways, it functions by nAD+ is a critical coenzyme in every cell, essential for mitochondrial energy production (oxidative phosphorylation), DNA repair via PARP and sirtuin activation, and circadian rhythm regulation. Levels decline ~50% between ages 40-60, contributing to metabolic dysfunction and aging. with a documented biological half-life of roughly 4 hours, in preclinical investigative trials and independent academic studies, researchers utilizing NAD+ have documented significant, quantifiable biological outcomes, primarily focusing on cellular energy, dna repair, longevity. Typical research protocols investigate administering 50000 to 200000mcg via subq pathways daily. However, it is critically important to understand that while NAD+ demonstrates profound physiological potential in highly controlled laboratory settings, it remains classified strictly as a research chemical and has not been approved by the United States Food and Drug Administration (FDA) for human therapeutic, diagnostic, or dietary consumption. Independent chemical analysis via rigorous third-party Certificate of Analysis (COA) testing utilizing High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) remains the industry gold standard for verifying its base elemental stability when reconstituted appropriately in sterile bacteriostatic water.
NAD+ is a critical coenzyme in every cell, essential for mitochondrial energy production (oxidative phosphorylation), DNA repair via PARP and sirtuin activation, and circadian rhythm regulation. Levels decline ~50% between ages 40-60, contributing to metabolic dysfunction and aging.
Rajman et al. (Cell Metabolism): Comprehensive review demonstrating NAD+ decline as a hallmark of aging, with restoration improving mitochondrial function, stem cell renewal, and lifespan in animal models.
strongZhang et al. (Science): NAD+ supplementation restores mitochondrial function in aged mice, improving muscle stem cell function and extending lifespan.
preclinicalCamacho-Pereira et al. (Cell Metabolism): Identifies CD38 as the primary NAD-consuming enzyme that increases with age, explaining the progressive NAD+ decline.
preclinicalYoshino et al.: Review of human clinical trials for NAD+ precursors (NMN, NR) showing safe elevation of blood NAD+ levels with improvements in insulin sensitivity and muscle function.
moderateGenerally well-tolerated. IV NAD+ infusions may cause chest tightness, nausea, and cramping during administration. Subcutaneous injection is better tolerated. Oral precursors (NMN, NR) have good safety profiles in clinical trials.
⚠️ For educational purposes only. Not medical advice. Consult a healthcare professional before using any peptide.
SubQ: 50-200mg daily. IV: 250-500mg over 2-4 hours. Start low — rapid NAD+ elevation can cause nausea and flushing. Oral precursors (NMN/NR) are an alternative.
Week 1
Increased energy, mental clarity, reduced brain fog
Weeks 2-4
Improved exercise recovery, better sleep quality, mood stabilization
Month 2-3
Measurable improvements in metabolic markers, sustained energy throughout the day
Long-term
NAD+ level restoration; potential longevity benefits (animal data for lifespan extension)
| Side Effect | Incidence | Severity |
|---|---|---|
Nausea during infusion Dose-dependent; resolved by slowing infusion rate | ~30% (IV route) | moderate |
Flushing/warmth | ~20% of users | mild |
Chest tightness Transient during infusion, resolves within minutes | ~15% (IV route) | mild |
Injection site discomfort | ~10% (SubQ) | mild |
Incidence rates sourced from published clinical trial data where available; otherwise based on community research observations.
Finding verified, high-purity NAD+ requires rigorous COA verification. We independently evaluate vendors based on third-party HPLC testing, purity thresholds (≥98%), and batch-specific documentation.
View COA-Verified NAD+✓ Third-party tested·✓ US shipping·✓ COA on every batch
Disclosure: PeptiDex may earn a commission from purchases made through affiliate links. This does not affect our editorial independence or recommendations. We exclusively feature vendors that pass our strict quality verification protocols.
PeptiDex. (2026). NAD+. PeptiDex Research Platform. https://peptidex.app/library/nad
12 stacks • exact dosages • cycle lengths • printable reference
No spam. Unsubscribe anytime.